APREA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.35 USD | -1.83% |
|
+2.88% | +13.83% |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 17.54 | 17.56 | 29.05 | - | - |
| Enterprise Value (EV) 1 | 17.54 | 17.56 | 29.05 | 29.05 | 29.05 |
| P/E ratio | -0.1 x | -1.19 x | -2.06 x | -3.42 x | -3.41 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | 30.1 x | 145 x | 145 x | 145 x |
| EV / Revenue | - | 30.1 x | 145 x | 145 x | 145 x |
| EV / EBITDA | -0.15 x | -1.14 x | -1.42 x | -1.24 x | -1.1 x |
| EV / FCF | -153,320 x | - | - | - | - |
| FCF Yield | -0% | - | - | - | - |
| Price to Book | - | - | - | - | - |
| Nbr of stocks (in thousands) | 2,650 | 3,737 | 5,430 | - | - |
| Reference price 2 | 6.620 | 4.700 | 5.350 | 5.350 | 5.350 |
| Announcement Date | 30/03/23 | 26/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 0.5832 | 0.2 | 0.2 | 0.2 |
| EBITDA 1 | - | -113.4 | -15.46 | -20.5 | -23.4 | -26.3 |
| EBIT 1 | - | -113.4 | -15.47 | -19.19 | -23.32 | -29.33 |
| Operating Margin | - | - | -2,652.81% | -9,594.66% | -11,660% | -14,664% |
| Earnings before Tax (EBT) 1 | - | -112.7 | -14.29 | -18.87 | -23.28 | -29.14 |
| Net income 1 | -37.13 | -112.7 | -14.29 | -18.87 | -23.28 | -29.14 |
| Net margin | - | - | -2,449.59% | -9,432.83% | -11,637.66% | -14,572.34% |
| EPS 2 | -34.80 | -67.99 | -3.950 | -2.597 | -1.563 | -1.567 |
| Free Cash Flow | - | -114.4 | - | - | - | - |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 15/03/22 | 30/03/23 | 26/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | 0.2497 | 0.3195 | - | - | - | - | 0.1967 | - |
| EBITDA 1 | - | - | -2.654 | -4.622 | -3.651 | -3.521 | -3.67 | -4.6 | -4.8 | -5.5 | -5.7 | - |
| EBIT 1 | -22.45 | -4.2 | -2.652 | -4.622 | -3.652 | -3.523 | -3.675 | -4.352 | -4.541 | -4.92 | -5.109 | -5.49 |
| Operating Margin | - | - | - | - | -1,462.49% | -1,102.72% | - | - | - | - | -2,597.75% | - |
| Earnings before Tax (EBT) 1 | -98.26 | -4.025 | -2.442 | -4.38 | -3.259 | -3.205 | -3.443 | -4.3 | -4.6 | -5.2 | -5.3 | -5.556 |
| Net income 1 | -98.26 | -4.025 | -2.442 | -4.38 | -3.259 | -3.205 | -3.443 | -4.3 | -4.6 | -5.2 | -5.3 | -5.556 |
| Net margin | - | - | - | - | -1,305.26% | -1,003.07% | - | - | - | - | -2,694.87% | - |
| EPS 2 | -86.80 | -2.400 | -0.9200 | -1.340 | -0.8700 | -0.8600 | -0.9200 | -0.7750 | -0.8050 | -0.8300 | -0.5350 | -1.000 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/08/22 | 09/11/22 | 30/03/23 | 15/05/23 | 10/08/23 | 09/11/23 | 26/03/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | -114 | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 15/03/22 | 30/03/23 | 26/03/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
5.35
USD
Average target price
15.67
USD
Spread / Average Target
+192.83%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +13.83% | 29.05M | |
| +25.69% | 47.86B | |
| +46.90% | 41.42B | |
| -3.46% | 40.66B | |
| -6.20% | 28.92B | |
| +9.17% | 25.55B | |
| -20.42% | 19.27B | |
| +0.17% | 12.15B | |
| +28.07% | 12.14B | |
| -1.24% | 11.99B |
- Stock Market
- Equities
- APRE Stock
- Financials Aprea Therapeutics, Inc.
